Physician profile
Sukesh Manthri
NPI 1508271859
$4,496.96
in general payments reported to CMS, 2019-2025
13 companies · $2,881 in 2025
The $2,881 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.00 · 2022: $352 · 2023: $268 · 2024: $984 · 2025: $2,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,920 · Long Term Medical Supply Or Device Loan: $1,879 · Food and Beverage: $308 · Education: $25.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,920.00 |
| Long Term Medical Supply Or Device Loan | $1,879.41 |
| Food and Beverage | $308.04 |
| Education | $25.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,232.10 | 2022-2025 | Imfinzi, Enhertu |
| Novartis Pharmaceuticals Corporation | $1,888.77 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $200.95 | 2022-2023 | Keytruda |
| Tactile Systems Technology INC | $49.19 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Tempus Ai, INC | $24.20 | 2024 | |
| Pfizer INC. | $21.39 | 2024 | |
| Coherus Oncology, INC. | $20.78 | 2023 | |
| Lilly USA, LLC | $17.11 | 2025 | Verzenio, Jaypirca, Retevmo |
| Ortho-Clinical Diagnostics, INC. | $16.47 | 2025 | Vitros |
| Astellas Pharma US INC | $14.00 | 2025 | Vyloy |
| Alexion Pharmaceuticals, INC. | $12.00 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sukesh Manthri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.